➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Pipamperone

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Pipamperone?

Pipamperone is an investigational drug.

There have been 4 clinical trials for Pipamperone. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2011.

The most common disease conditions in clinical trials are Schizophrenia, Disease, and Depressive Disorder, Major. The leading clinical trial sponsors are PharmaNeuroBoost N.V., Hannover Medical School, and [disabled in preview].

There are two US patents protecting this investigational drug and seventeen international patents.

Recent Clinical Trials for Pipamperone
Pharmacovigilance in Gerontopsychiatric PatientsHannover Medical SchoolPhase 3
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic SchizophreniaPharmaNeuroBoost N.V.Phase 2
Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)PharmaNeuroBoost N.V.Phase 3

See all Pipamperone clinical trials

Clinical Trial Summary for Pipamperone

Top disease conditions for Pipamperone
Top clinical trial sponsors for Pipamperone

See all Pipamperone clinical trials

US Patents for Pipamperone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pipamperone   Get Started Free Quinolone-based compounds, formulations, and uses thereof University of South Florida (Tampa, FL) Northeastern University (Boston, MA)   Get Started Free
Pipamperone   Get Started Free Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Get Started Free
Pipamperone   Get Started Free Compositions and methods for treating Dengue virus infection The J. David Gladstone Institutes (San Francisco, CA) The Regents of the University of California (Oakland, CA)   Get Started Free
Pipamperone   Get Started Free Compounds useful for the treatment of metabolic disorders and synthesis of the same North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pipamperone

Drugname Country Document Number Estimated Expiration Related US Patent
Pipamperone China CN103987697 2031-10-14   Get Started Free
Pipamperone European Patent Office EP2766345 2031-10-14   Get Started Free
Pipamperone European Patent Office EP2899183 2031-10-14   Get Started Free
Pipamperone Spain ES2572908 2031-10-14   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.